Literature DB >> 16003063

Deep venous thrombosis in medical-surgical critically ill patients: prevalence, incidence, and risk factors.

Deborah Cook1, Mark Crowther, Maureen Meade, Christian Rabbat, Lauren Griffith, David Schiff, William Geerts, Gordon Guyatt.   

Abstract

OBJECTIVE: Critically ill patients may be at high risk of venous thromboembolism. The objective was to determine the prevalence, incidence, and risk factors for proximal lower extremity deep venous thrombosis among critically ill medical-surgical patients.
DESIGN: Prospective cohort.
SETTING: Closed university-affiliated intensive care unit. PATIENTS: We enrolled consecutive patients > or =18 yrs of age expected to be in intensive care unit for > or =72 hrs. Exclusion criteria were an admitting diagnosis of trauma, orthopedic surgery, pregnancy, and life support withdrawal.
INTERVENTIONS: Interventions included bilateral lower extremity compression ultrasound within 48 hrs of intensive care unit admission, twice weekly, and if venous thromboembolism was clinically suspected. Thromboprophylaxis was protocol directed and universal. We recorded deep venous thrombosis risk factors at baseline and daily, using multivariate regression analysis to determine independent predictors. Patients were followed to hospital discharge.
RESULTS: Among 261 patients with a mean Acute Physiology and Chronic Health Evaluation II score of 25.5 (+/-8.4), the prevalence of deep venous thrombosis was 2.7% (95% confidence interval 1.1-5.5) on intensive care unit admission, and the incidence was 9.6% (95% confidence interval 6.3-13.8) over the intensive care unit stay. We identified four independent risk factors for intensive care unit-acquired deep venous thrombosis: personal or family history of venous thromboembolism (hazard ratio 4.0, 95% confidence interval 1.5-10.3), end-stage renal failure (hazard ratio 3.7, 95% confidence interval 1.2-11.1), platelet transfusion (hazard ratio 3.2, 95% confidence interval 1.2-8.4), and vasopressor use (hazard ratio 2.8, 95% confidence interval 1.1-7.2). Patients with deep venous thrombosis had a longer duration of mechanical ventilation (p = .03), intensive care unit stay (p = .005), and hospitalization (p < .001) than patients without deep venous thrombosis.
CONCLUSIONS: Despite universal thromboprophylaxis, medical-surgical critically ill patients remain at risk for lower extremity deep venous thrombosis. Further research is needed to evaluate the risks and benefits of more intense venous thromboembolism prophylaxis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16003063     DOI: 10.1097/01.ccm.0000171207.95319.b2

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  92 in total

1.  Physicians declining patient enrollment in a critical care trial: a case study in thromboprophylaxis.

Authors:  D Cook; Y Arabi; N Ferguson; D Heels-Ansdell; A Freitag; E McDonald; F Clarke; S Keenan; G Pagliarello; W Plaxton; M Herridge; T Karachi; S Vallance; J Cade; T Crozier; S Alves da Silva; R Costa Filho; N Brandao; I Watpool; T McArdle; G Hollinger; Y Mandourah; M Al-Hazmi; N Zytaruk; N K J Adhikari
Journal:  Intensive Care Med       Date:  2013-12       Impact factor: 17.440

2.  Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Susan R Kahn; Wendy Lim; Andrew S Dunn; Mary Cushman; Francesco Dentali; Elie A Akl; Deborah J Cook; Alex A Balekian; Russell C Klein; Hoang Le; Sam Schulman; M Hassan Murad
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

3.  Association between aspirin use and deep venous thrombosis in mechanically ventilated ICU patients.

Authors:  Ena Gupta; Furqan S Siddiqi; Ryan Kunjal; Muhammad Faisal; Farah Al-Saffar; Abubakr A Bajwa; Lisa M Jones; Vandana Seeram; James D Cury; Adil Shujaat
Journal:  J Thromb Thrombolysis       Date:  2017-10       Impact factor: 2.300

4.  Observational vs randomized: David vs Goliath for thromboprophylaxis in critically ill patients?

Authors:  Julie Helms; Julian Bion; Audrey De Jong
Journal:  Intensive Care Med       Date:  2019-01-28       Impact factor: 17.440

Review 5.  Thromboprophylaxis with low molecular weight heparin versus unfractionated heparin in intensive care patients: a systematic review with meta-analysis and trial sequential analysis.

Authors:  Sigrid Beitland; Irene Sandven; Lill-Kristin Kjærvik; Per Morten Sandset; Kjetil Sunde; Torsten Eken
Journal:  Intensive Care Med       Date:  2015-05-14       Impact factor: 17.440

Review 6.  The impact of deep vein thrombosis in critically ill patients: a meta-analysis of major clinical outcomes.

Authors:  Alessandra Malato; Francesco Dentali; Sergio Siragusa; Francesco Fabbiano; Yoan Kagoma; Maria Boddi; Gian Franco Gensini; Adriano Peris; Mark Crowther; Mariasanta Napolitano
Journal:  Blood Transfus       Date:  2015-10       Impact factor: 3.443

7.  Factor VIII May Predict Catheter-Related Thrombosis in Critically Ill Children: A Preliminary Study.

Authors:  Edward Vincent S Faustino; Simon Li; Cicero T Silva; Matthew G Pinto; Li Qin; Joana A Tala; Henry M Rinder; Gary M Kupfer; Eugene D Shapiro
Journal:  Pediatr Crit Care Med       Date:  2015-07       Impact factor: 3.624

8.  Bioactivity of enoxaparin in critically ill patients with normal renal function.

Authors:  Ghazaleh Gouya; Stefan Palkovits; Stylianos Kapiotis; Christian Madl; Gottfried Locker; Alexander Stella; Michael Wolzt; Gottfried Heinz
Journal:  Br J Clin Pharmacol       Date:  2012-11       Impact factor: 4.335

Review 9.  The platelet as an immune cell-CD40 ligand and transfusion immunomodulation.

Authors:  Neil Blumberg; Sherry L Spinelli; Charles W Francis; Mark B Taubman; Richard P Phipps
Journal:  Immunol Res       Date:  2009-01-29       Impact factor: 2.829

10.  Enoxaparin, effective dosage for intensive care patients: double-blinded, randomised clinical trial.

Authors:  Sian Robinson; Aleksander Zincuk; Thomas Strøm; Torben Bjerregaard Larsen; Bjarne Rasmussen; Palle Toft
Journal:  Crit Care       Date:  2010-03-18       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.